Reuters logo
BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan
April 22, 2014 / 12:45 PM / 3 years ago

BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan

April 22 (Reuters) -

* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan

* Positive results from this study will help support a potential filing of FF/VI for treatment of patients with COPD in Japan.

* Study will evaluate contribution of ICS component on lung function, in patients with chronic obstructive pulmonary disease (COPD)

* GSK chose to withdraw COPD file in Japan while designing an additional study

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below